• Biology, Medicine
  • Published in
    Current opinion in…
    2010

Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.

@article{Klibanov2010CenicrivirocAO,
  title={Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.},
  author={Olga M. Klibanov and Shannon H Williams and Cameron A Iler},
  journal={Current opinion in investigational drugs},
  year={2010},
  volume={11 8},
  pages={
          940-50
        }
}
Treatment of HIV-1-infected individuals is often complicated by the development of antiretroviral resistance, and novel antiretroviral agents with unique mechanisms of action and resistance profiles are needed to address this issue. CCR5 inhibitors represent a new class of antiretroviral agents that block the CCR5 receptor and prevent HIV-1 recognition and entry into CD4+ macrophages and T-cells. Tobira Therapeutics Inc is developing cenicriviroc (TBR-652, formerly TAK-652), a potent inhibitor… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

Cancer-associated adipocytes: key players in breast cancer progression

VIEW 20 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study

  • Zhen Wang, Hansu Park, Eun Ju Bae
  • Biology, Medicine
  • The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND